LV PHARMA - Company finances
|
EUR
|
2021
From: 2021-05-25
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | 1,870 | 9,520 | 8,670 | 9,460 | 13,160 |
| Profit before tax | - | - | - | - | - |
| Net profit | -1,261 | 142 | -708 | 99 | 405,124 |
| Equity | 1,239 | 1,381 | 673 | 772 | 405,896 |
| Liabilities | 0 | 0 | 2 | 0 | 512 |
| Non-current assets | 437 | 437 | 447 | 447 | 10 |
| Current assets | 802 | 944 | 228 | 325 | 406,398 |
| Total assets | 1,239 | 1,381 | 675 | 772 | 406,408 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 1,978 | 1,928 | 1,595 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | +409.1% | -8.9% | +9.1% | +39.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -101.8% | 10.3% | -104.9% | 12.8% | 99.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -101.8% | 10.3% | -105.2% | 12.8% | 99.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -67.4% | 1.5% | -8.2% | 1.0% | 3078.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | 0.0 | - | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 935 | 4,760 | 4,335 | 4,730 | 8,773 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
LV PHARMA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-05-16 | 2024-05-20 | 0.13 |
LV PHARMA - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-08-02 | 2026-08-30 | 0.17 |
| 2025-01-31 | 2025-02-14 | 0.02 |
| 2025-01-17 | 2025-01-30 | 0.55 |
| 2025-01-14 | 2025-01-16 | 49.93 |
| 2024-09-11 | 2024-10-13 | 0.01 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
LV PHARMA, UAB (code 305776345) is a Private Limited Liability Company engaged in wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of EUR 13.2K, up 39.1% year on year and 51.8% over two years. Profitability improved sharply: net profit reached EUR 405.1K, compared with EUR 99 in 2024 and a loss of EUR 708 in 2023. The 2023–2025 trajectory therefore shows a move from a small loss to a small profit and then to a very strong positive result in 2025. Because the profit increase is very large relative to the revenue base, margin and return ratios should be interpreted cautiously and are better viewed as evidence of an exceptional year than as a stable operating level. At the end of 2025, total assets were EUR 406.4K, equity EUR 405.9K and liabilities EUR 512, indicating a balance sheet financed almost entirely by equity. Revenue per employee was EUR 13.2K, while asset turnover remained low at 0.03x.